Arvinas to Join Upcoming Investor Conferences
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology firm dedicated to developing innovative drugs through targeted protein degradation, has announced its participation in two important investor conferences.
Details on Upcoming Conferences
The first event on the agenda is the Wells Fargo Healthcare Conference, scheduled for a Thursday in September. Representing Arvinas will be Ian Taylor, Ph.D., the President of R&D, alongside Randy Teel, Ph.D., the Chief Business Officer. They will participate in a prominent fireside chat during the event. Those interested can tune in to a live audio webcast of the discussion on the company’s website.
Wells Fargo Healthcare Conference
This conference offers a valuable opportunity for investors to gain insights into Arvinas' research and development strategies. The discussions are anticipated to highlight the latest advancements related to the company’s pioneering therapies.
Cantor Global Healthcare Conference
The second event on the calendar is the Cantor Global Healthcare Conference, also taking place on a Thursday in September. Arvinas will be featured in a discussion with Noah Berkowitz, MD, Ph.D., the Chief Medical Officer, and Andrew Saik, the Chief Financial Officer. Similar to the previous conference, a live audio webcast will be provided, allowing those unable to attend in person to stay updated on the latest developments from the company.
Exciting Presentations Ahead
Both conferences present a significant opportunity for Arvinas to provide updates on its clinical trials and the pipeline of investigational drugs. Investors will gain insights into how Arvinas intends to improve patient care through its innovative strategies.
About Arvinas
Arvinas is committed to enhancing the lives of patients dealing with serious and life-threatening conditions. By utilizing its PROTAC (PROteolysis Targeting Chimera) platform, the company is at the forefront of developing therapies designed to boost the body’s capacity to degrade and eliminate proteins that contribute to disease.
Advancing Innovative Drug Development
The company is actively progressing several investigational drugs within its clinical development programs. Noteworthy candidates include vepdegestrant, which targets the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, aimed at LRRK2 for neurodegenerative disorders; and ARV-393, which targets BCL6 for patients with relapsed/refractory non-Hodgkin lymphoma. Each of these therapies exemplifies Arvinas' dedication to tackling complex medical challenges through innovative solutions.
Contact Information for the Company
For any inquiries, please reach out to:
Investors:
Jeff Boyle
+1 (347) 247-5089
Email: Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Email: Kirsten.Owens@arvinas.com
Frequently Asked Questions
What are the upcoming investor conferences for Arvinas?
Arvinas will participate in the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference.
Who will represent Arvinas at these conferences?
Ian Taylor and Randy Teel will represent Arvinas at the Wells Fargo Healthcare Conference, while Noah Berkowitz and Andrew Saik will participate in the Cantor Global Healthcare Conference.
What is the focus of Arvinas as a biotechnology company?
Arvinas focuses on drug development based on targeted protein degradation, leveraging its unique PROTAC platform.
What are some of the investigational drugs being developed by Arvinas?
Key investigational drugs include vepdegestrant, ARV-102, and ARV-393, targeting various serious health conditions.
How can I get in touch with Arvinas for investment inquiries?
Investors can contact Jeff Boyle via phone at +1 (347) 247-5089 or via email at Jeff.Boyle@arvinas.com.